Completed PHASE3 INTERVENTIONAL NCT00061022

Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

SAINT (Stroke - Acute Ischemic - NXY Treatment) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke

Sponsor: AstraZeneca

Conditions Cerebral Stroke Cerebrovascular Stroke Ischemic Attack, Transient Stroke, Acute

Interventions NXY-059

Updated 6 times since 2017 Last updated: Nov 10, 2010 Started: May 31, 2003 Primary completion: Sep 30, 2006 Completion: Sep 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00061022, this PHASE3 trial focuses on Cerebral Stroke and Cerebrovascular Stroke and remains completed. Sponsored by AstraZeneca, it has been updated 6 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarau, Switzerland , Abington, United States , Aguascalientes, Mexico , Amadora, Portugal , Ann Arbor, United States , Antwerp, Belgium , Anyang, South Korea , Arcadia, United States , Asheville, United States , Ashkelon, Israel and 245 more locations